4WEB Medical Receives 510(k) Clearance to Market Their Lumbar Plating Solution

4WEB Medical notes the new plating solution consists of a wide variety of modular plating configurations to address multiple lumbar spine pathologies and approaches.

The device provides an integrated and non-integrated offering with a one, two, and four screw option. The plate design also features a single-step locking mechanism to prevent screw backout.

“Our continued commitment to new product development led to revenue growth in FY 2020 driven by the launch of the Stand Alone Cervical and ALIF product lines,”  said Jim Bruty, Sr. Vice President of Sales and Marketing at 4Web Medical. “The Lumbar Plating Solution will contribute significantly to 2021 top-line growth by enabling surgeon customers to utilize the company’s Truss Implant Technology in more advanced lateral procedures such as anterior longitudinal ligament release techniques.”

The latest addition to the 4WEB portfolio further demonstrates the company’s commitment to developing a comprehensive lateral spine program. 4Web Medical currently has procedural-based solutions developed for Direct Lateral, Anterior-to-Psoas (ATP),  and Prone Lateral approaches to the lumbar spine. The company also has dedicated resources for the future development of a novel lateral deformity solution.

4WEB Medical expects to launch its hyperlordotic lateral implant line and an Anterior-to-Psoas implant by the end of the year making the 4WEB Total Lateral Solution one of the most comprehensive offerings in the lateral spine space.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.